Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection

Graham R Foster, Stephen Pianko, Ashley Brown, Daniel M Forton, Ronald G Nahass, Jacob George, Eleanor Barnes, Diana Brainard, Benedetta Massetto, Ming Lin, Bin Han, John G McHutchison, G Mani Subramanian, Curtis Cooper, Kosh Agarwal

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA
Original languageEnglish
Pages (from-to)1462 - 1470
Number of pages9
JournalGastroenterology
Volume149
Issue number6
DOIs
Publication statusPublished - 2015

Cite this

Foster, Graham R ; Pianko, Stephen ; Brown, Ashley ; Forton, Daniel M ; Nahass, Ronald G ; George, Jacob ; Barnes, Eleanor ; Brainard, Diana ; Massetto, Benedetta ; Lin, Ming ; Han, Bin ; McHutchison, John G ; Subramanian, G Mani ; Cooper, Curtis ; Agarwal, Kosh. / Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. In: Gastroenterology. 2015 ; Vol. 149, No. 6. pp. 1462 - 1470.
@article{85644ed9de57466fb15c64e85f65af23,
title = "Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection",
abstract = "Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA",
author = "Foster, {Graham R} and Stephen Pianko and Ashley Brown and Forton, {Daniel M} and Nahass, {Ronald G} and Jacob George and Eleanor Barnes and Diana Brainard and Benedetta Massetto and Ming Lin and Bin Han and McHutchison, {John G} and Subramanian, {G Mani} and Curtis Cooper and Kosh Agarwal",
year = "2015",
doi = "10.1053/j.gastro.2015.07.043",
language = "English",
volume = "149",
pages = "1462 -- 1470",
journal = "Gastroenterology",
issn = "0016-5085",
number = "6",

}

Foster, GR, Pianko, S, Brown, A, Forton, DM, Nahass, RG, George, J, Barnes, E, Brainard, D, Massetto, B, Lin, M, Han, B, McHutchison, JG, Subramanian, GM, Cooper, C & Agarwal, K 2015, 'Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection' Gastroenterology, vol. 149, no. 6, pp. 1462 - 1470. https://doi.org/10.1053/j.gastro.2015.07.043

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. / Foster, Graham R; Pianko, Stephen; Brown, Ashley; Forton, Daniel M; Nahass, Ronald G; George, Jacob; Barnes, Eleanor; Brainard, Diana; Massetto, Benedetta; Lin, Ming; Han, Bin; McHutchison, John G; Subramanian, G Mani; Cooper, Curtis; Agarwal, Kosh.

In: Gastroenterology, Vol. 149, No. 6, 2015, p. 1462 - 1470.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection

AU - Foster, Graham R

AU - Pianko, Stephen

AU - Brown, Ashley

AU - Forton, Daniel M

AU - Nahass, Ronald G

AU - George, Jacob

AU - Barnes, Eleanor

AU - Brainard, Diana

AU - Massetto, Benedetta

AU - Lin, Ming

AU - Han, Bin

AU - McHutchison, John G

AU - Subramanian, G Mani

AU - Cooper, Curtis

AU - Agarwal, Kosh

PY - 2015

Y1 - 2015

N2 - Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA

AB - Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA

UR - http://www.gastrojournal.org/article/S0016-5085(15)01069-0/pdf

U2 - 10.1053/j.gastro.2015.07.043

DO - 10.1053/j.gastro.2015.07.043

M3 - Article

VL - 149

SP - 1462

EP - 1470

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -